



Published in final edited form as:

Org Lett. 2018 July 06; 20(13): 3793–3796. doi:10.1021/acs.orglett.8b01387.

An Oxidative Dearomatization Approach to Prepare the Pentacyclic Core of Ryanodol

Chen Xu^{*,†,‡}, Arthur Han[‡], and Sarah E. Reisman^{*,‡}


[†] Shenzhen Grubbs Institute, Southern University of Science and Technology (SUSTech), Shenzhen, 518055, China

[‡] The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States

Abstract

An approach to synthesize the pentacyclic framework of the polyol diterpenoid ryanodol is reported. The ABC tricycle was constructed by a Comediated Pauson-Khand reaction, and both radical and anionic cyclization pathways were developed to form the E-ring. In addition, a reaction sequence involving SeO₂-mediated enone oxidation and hydroxyl-directed oxy-Michael addition was developed to introduce the A-ring oxidation. The feasibility of forming the bridging D-ring by an oxidative dearomatization was established.

Abstract



Ryanodine (1) is a diterpenoid natural product that was isolated from the insecticidal shrub *Ryania speciosa* Vahl in 1958 (Figure 1).¹ Investigations of ryanodine's insecticidal properties ultimately led to the identification of the ryanodine receptors (RyRs), high conductance intracellular calcium ion channels that are involved in biological signaling pathways such as excitation-contraction coupling.^{2,3} Ryanodine binds to the open state of RyRs with high affinity and is widely used as a probe molecule to interrogate the functional state of RyRs.⁴ Hydrolysis of the C3-ester of ryanodine provides ryanodol,^{1b,5} a compound

*Corresponding Author: xuc@sustc.edu.cn, reisman@caltech.edu.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Experimental procedures, characterization data (¹H and ¹³C NMR, HRMS, FTIR) for all new compounds (pdf)

that retains affinity for insect RyRs but exhibits significantly lower affinity for the mammalian receptors. In addition to ryanodine, a series of related ryanoids with variations in the peripheral oxidation have been isolated over the past several decades (e.g. **3**, **4**, **5**).⁶ Whereas the pharmacology of ryanodine has been extensively investigated,⁷ far less is known about the biological activities of these minor ryanoid natural products. As part of a program aimed at the development of new ryanoid probes of RyR function, we initiated a synthetic effort to prepare ryanodol, ryanodine, and related ryanoid congeners.

Although our long-term objective was to prepare ryanodine (**1**), initial studies focused on the hydrolysis product, ryanodol (**2**), to validate our synthetic strategy. Structural analysis of ryanodol identified the central bridging D and E rings as opportunities for strategic disconnections (Scheme 1). Prior work by Deslongchamps and coworkers had established that **2** can be prepared in two steps from anhydroryanodol (**6**),⁸ establishing the viability of late-stage E-ring formation. In 2016, we reported a 13-step synthesis of anhydroryanodol from (S)-pulegone (**7**)⁹ and subsequently demonstrated that a similar approach furnishes (+)-ryanodine (**1**) in 18 steps.^{10,11}

Our successful syntheses of **1** and **2** were heavily guided by a first-generation approach to **2**, wherein we envisioned late-stage formation of the D-ring by an oxidative dearomatization of phenol **8** (Scheme 1). Phenol **8** was expected to be accessible by a radical or anionic cyclization of **9a** or **9b**, either of which could be prepared from the product of a Pauson-Khand reaction¹² of enyne **10**. Enyne **10** could be prepared from arene **11**. An appealing aspect of this approach is that it would enable divergent, late-stage oxidation of the C-ring, which could provide access to additional ryanoids such as ga-rajonone (**3**), 2,3-didehydrocinnzeylanone (**4**), or 9-hydroxy-10-epi-ryanodine (**5**, Figure 1). In this report, we disclose the chemistry developed as part of our first-generation approach to ryanodol (**2**). While this approach was not ultimately used to prepare **1** and **2**, these studies established that the carbocyclic framework of ryanodol can be prepared by an oxidative dearomatization. In addition, these studies identified the use of a Pauson-Khand reaction to prepare the ABC tricycle, and a sequence for A-ring functionalization involving SeO₂-mediated cyclopentenone oxidation and isopropenyl cross-coupling, tactics that were incorporated into the successful syntheses of **1** and **2**.^{9,10}

The first objective of our preliminary investigations was to validate the feasibility of preparing the pentacyclic ryanodol core by an oxidative dearomatization. To this end, phenol **12**¹³ was protected as the methyl ether and the iodide was chemoselectively cross-coupled with n-butyl vinyl ether via a Pd-catalyzed Heck reaction,¹⁴ which upon acidic workup delivered ketone **13** (Scheme 2). Sonogashira coupling of the bromide with propyne furnished alkyne **14** in 77% yield.¹⁵ Subsequent 1,2-addition of vinylmagnesium bromide to the methyl ketone afforded the tertiary alcohol (**10**, Scheme 1), which underwent a Co-mediated Pauson-Khand cyclization and acid-catalyzed dehydration to afford tricyclic enone **15**.¹⁶ This efficient, six-step protocol readily establishes the ABC tricycle present in the ryanoids, and has been executed on multigram scale.

At this stage, benzyl ether **16** was also prepared to enable exploratory studies wherein the phenol could be revealed under mild conditions. Both the methyl (**15**) and benzyl (**16**) ethers

were advanced to the corresponding cyclopentenones **20** and **21**. This two-step sequence introduces the first of two all-carbon quaternary centers via chemoselective epoxidation of the more electron rich alkene, followed by Lewis acid-catalyzed epoxide opening with silyl ketene acetal **19**.¹⁷

Initial studies focused on E-ring formation from methyl ether **20**. 1,2-Addition of isopropyl magnesium chloride to **20** in the presence of $\text{CeCl}_3 \cdot 2\text{LiCl}$ delivered the isopropyl group from the α -face (Scheme 3).¹⁸ Hydrolysis of the methyl ester was followed by conversion of the acid to the acyl selenide **23**. Treatment of **23** with $(\text{TMS})_3\text{SiH}$ and AIBN resulted in acyl radical cyclization to provide tetracyclic ketone **24** in moderate yield. Notably, the isomeric product resulting from radical addition to C12 was not observed; this product is likely disfavored due to the strain associated with a *transfused* 5–5 ring system.¹⁹ Tetracycle **24** was advanced to an oxidative cyclization substrate, **25**, by $\text{NaBH}(\text{OAc})_3$ reduction of the C15 ketone followed by nucleophilic demethylation of the phenol. The stereoselectivity of the $\text{NaBH}(\text{OAc})_3$ reduction was confirmed by NOESY.²⁰ Treatment of phenol **25** with $\text{PhI}(\text{OAc})_2$ led to clean formation of the desired *ortho*-oxidative dearomatization product **26** bearing the complete pentacyclic ryanoid carbon skeleton. Hydroxyl-directed epoxidation with *m*-CPBA followed by hydrogenolysis of the allylic epoxide afforded **27**. Pentacycle **27** has the fully functionalized C ring of the natural ryanoid 2,3-didehydro-cinzeylanone (**4**), but lacks the C12 and C15 alcohols. Nonetheless, these studies validated the feasibility of an oxidative dearomatization approach to prepare the ryanoid framework.

Recognizing that it would be difficult to introduce the C12 and C15 alcohols through existing C-H oxidation technologies, we investigated a second approach in which the hydroxyl group at C12 would be introduced prior to oxidative dearomatization (Scheme 4). Riley oxidation of enone **21** under microwave irradiation provided diketone **28**.²¹ We were pleased to find that condensation of the tertiary alcohol of **28** with $^n\text{BuB}(\text{OH})_2$ enabled intramolecular oxy-Michael addition; *in situ* trapping of the resulting enolate with Tf_2O afforded triflate **29** in a one-pot procedure.²² The reactive enediketone of **28** is required for the oxy-Michael addition, as enone **21** did not undergo the corresponding reaction. Suzuki cross-coupling of vinyltriflate **29**, followed by cleavage of the labile cyclic boronate provided diol **32**.

With access to the fully functionalized ABC tricycle, we turned our attention to the installation of a functional group (FG) precursor that could ultimately furnish the required hydroxyl at C15 (Scheme 4). To this end, methyl ester **32** was saponified and converted to acyl selenide **33**, which upon exposure to Bu_3SnH and AIBN at 80 °C underwent intramolecular acyl radical cyclization to provide tetracycle **34**. Unfortunately, efforts to convert diketone **34** to tertiary alcohols, such as **35**, using a variety of nucleophiles (TMSCN , vinyl Grignard, ethynyl Grignard, etc.) were unsuccessful due to competitive addition to the C3 ketone, or incorrect diastereoselectivity at C15. Given the propensity of nucleophiles to approach the C15 ketone from the sterically less encumbered trajectory (over the arene), we envisioned that dihydroxylation of a tetracycle bearing an C15 *exo*-methylene would provide a tertiary alcohol with the required configuration (e.g. **35**, $\text{FG} = \text{CH}_2\text{OH}$). The required C15 hydroxyl group could be revealed via a Baeyer-Villiger protocol.

To this end, *exo*-olefin **42** was prepared by first adding allenyl stannane **36** to epoxide **18** to give tertiary alcohol **37** as a single diastereomer in 53% yield (Scheme 5).²³ The alkyne of **37** was elaborated to vinyl iodide **38** by regioselective stannylaluminum/protonolysis with Bu₃SnAlEt₂/CuCN and subsequent iododestannylation.²⁴ Hydroxyl-directed epoxidation of **38**, followed by protection of the tertiary alcohol with TESCl furnished **40**. Treatment of **40** with ⁿBuLi in THF at 0 °C provided the the desired 1,2 addition product **41** in 65% yield, which underwent a facile semi-pinacol rearrangement in the presence of TMSOTf and 2,6-lutidine to give tetracycle **42** with the critical vicinal yn-diol at the AB ring fusion. Unfortunately, dihydroxylation of the *exo*-olefin of **42** proceeded with high diastereoselectivity for the incorrect diol stereoisomer, **43** (confirmed by NOESY data). Efforts to oxidize this terminal alkene by the Prévost reaction,²⁵ Woodward reaction,²⁶ or Sharpless dihydrox-ylation²⁷ failed to produce the desired diol.

These studies established the viability of preparing the ryanodol carbon framework by an oxidative dearomatization approach. Although this strategy did not successfully provide access to the natural product targets, it established several key chemistries that were incorporated into the completed route.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

We thank Dr. Michael Takase and Larry Henling (both of Caltech) for X-ray data collection and Ms. Julie Hofstra (Caltech) for X-ray data refinement. Dr. Scott Virgil and the Caltech Center for Catalysis and Chemical Synthesis are gratefully acknowledged for access to analytical equipment. Fellowship support was provided by the Shenzhen UVChemTech Inc. (C.X.), and the NIH (A. H., 5T32GM007616–37, 1F31GM120821). S.E.R. is a Heritage Medical Research Institute Investigator. Financial support from the NIH (NIGMS RGM097582–01, R35GM118191–01), Eli Lilly, and Novartis is gratefully acknowledged.

REFERENCES

- (1). (a) Rogers EF; Koniuszy FR; Shavel J; Folkers K J. Am. Chem. Soc 1948, 70, 3086–3088. [PubMed: 18882544] (b) Wiesner K; Valenta Z; Findlay JA Tetrahedron Lett. 1967, 8, 221.
- (2). (a) Pessah IN; Waterhouse AL; Casida JE Biochem. Biophys. Res. Commun 1985, 128, 449–456. [PubMed: 3985981] (b) Inui M; Saito A; Fleischer S J. Biol. Chem 1987, 262, 15637–15642. [PubMed: 3680217]
- (3). (a) Ryanodine Receptors: Structure, Function and Dysfunction in Clinical Disease. Wehrens XHT; Marks AR, Eds.; Springer: 2005. (b) Lanner JT Ryanodine Receptor Physiology and Its Role in Disease In Calcium Signaling, Islam MS, Ed.; Advances in Experimental Medicine and Biology; Springer: 2012.
- (4). (a) Meissner G J Biol. Chem 1986, 261, 6300–6306. [PubMed: 2422165] (b) Meissner G; El-Hashem A Mol. Cell. Biochem 1992, 114, 119–123. [PubMed: 1334225]
- (5). Srivastava SN; Przybylska M Can. J. Chem 1968, 46, 795–797.
- (6). Garajonone and 2,3-didehydro-cinnzeylanone: (a) Fraga BM; Terrero D; Gutierrez C; Gonzalez-Coloma A Phytochemistry 2001, 56, 315 9-Hydroxy-10-epi-ryanodine: [PubMed: 11249093] (b) Hübner H; Vierling W; Brandt W; Reiter M; Achenbach H Phytochemistry 2001, 57, 285. [PubMed: 11382246]
- (7). Sutko JL; Airey JA; Welch W; Ruest L Pharmacol. Rev 1997, 49, 53–98. [PubMed: 9085309]

- (8). (a) Deslongchamps P; Bélanger A; Berney DJF; Borschberg HJ; Brousseau R; Doutheau A; Durand R; Katayama H; Lapalme R; Leturc DM; Liao CC; MacLachlan FN; Maffrand JP; Marazza F; Martino R; Moreau C; Ruest L; Saint-Laurent L; Saintonge R; Soucy P *Can. J Chem* 1979, 57, 3348–3354. (b) Deslongchamps P; Bélanger A; Berney DJF; Borschberg HJ; Brousseau R; Doutheau A; Durand R; Katayama H; Lapalme R; Leturc DM; Liao CC; MacLachlan FN; Maffrand JP; Marazza F; Martino R; Moreau C; Ruest L; Saint-Laurent L; Saintonge R; Soucy P *Can. J Chem* 1990, 68, 115–126. (c) Deslongchamps P; Bélanger A; Berney DJF; Borschberg HJ; Brousseau R; Doutheau A; Durand R; Katayama H; Lapalme R; Leturc DM; Liao CC; MacLachlan FN; Maffrand JP; Marazza F; Martino R; Moreau C; Ruest L; Saint-Laurent L; Saintonge R; Soucy P *Can. J Chem* 1990, 68, 127–152. (d) Deslongchamps P; Bélanger A; Berney DJF; Borschberg HJ; Brousseau R; Doutheau A; Durand R; Katayama H; Lapalme R; Leturc DM; Liao CC; MacLachlan FN; Maffrand JP; Marazza F; Martino R; Moreau C; Ruest L; Saint-Laurent L; Saintonge R; Soucy P *Can. J Chem* 1990, 68, 153–185. (e) Deslongchamps P; Bélanger A; Berney DJF; Borschberg HJ; Brousseau R; Doutheau A; Durand R; Katayama H; Lapalme R; Leturc DM; Liao CC; MacLachlan FN; Maffrand JP; Marazza F; Martino R; Moreau C; Ruest L; Saint-Laurent L; Saintonge R; Soucy P *Can. J Chem* 1990, 68, 186–192.
- (9). Chuang KV; Xu C; Reisman SE *Science* 2016, 353, 912–915. [PubMed: 27563092]
- (10). Xu C; Han A; Virgil SC; Reisman SE *ACS Cent. Sci* 2017, 3, 278–282.
- (11). In addition, Inoue and coworkers have reported syntheses of ryanodol and ryanodine: (a) Nagatomo M; Koshimizu M; Masuda K; Tabuchi T; Urabe D; Inoue M *J. Am. Chem. Soc* 2014, 136, 5916–5919. [PubMed: 24708178] (b) Nagatomo M; Hagiwara K; Masuda K; Koshimizu M; Kawamata T; Matsui Y; Urabe D; Inoue M *Chem. Eur. J* 2016, 22, 222–229. [PubMed: 26616151] (c) Masuda K; Koshimizu M; Nagatomo M; Inoue M *Chem. Eur. J* 2016, 22, 230–236. [PubMed: 26616265]
- (12). (a) Khand IU; Knox GR; Pauson PL; Watts WE; Forman MI *J. Chem. Soc. Perkin Trans. I* 1973, 1973, 977–981. (b) Chung YK; Lee BY; Jeong N; Hudecek M; Pauson PL *Organometallics*, 1993, 12, 220–223 (1993). (c) Shambayani S; Crowe WE; Schreiber SL *Tetrahedron Lett.* 1990, 31, 5289–5292.
- (13). Prepared in one step from commercially available 11 using the following method: Fujisaki S; Eguchi H; Omura A; Okamoto A; Nishida A *Bull. Chem. Soc. Jpn* 1993, 66, 1576–1579.
- (14). Hyder Z; Ruan J; Xiao J *Chem. Eur. J* 2008, 14, 5555. [PubMed: 18478518]
- (15). Hundertmark T; Littke AF; Buchwald SL; Fu GC *Org. Lett* 2000, 2, 1729–1731. [PubMed: 10880212]
- (16). Chung YK; Lee BY; Jeong N; Hudecek M; Pauson PL *Organometallics* 1993, 12, 220.
- (17). Silyl ketene acetal 19 was prepared according to: Wenzel AG; Jacobsen EN *J. Am. Chem. Soc* 2002, 124, 12964–12965. [PubMed: 12405820]
- (18). Krasovskiy A; Kopp F; Knochel P *Angew. Chem. Int. Ed* 2006, 45, 497–500.
- (19). It is possible that 24 arises by initial 5-exo-trig cyclization followed by Dowd-Beckwith-type rearrangement to give the more thermodynamically favored product. (a) Dowd P; Choi SC *J. Am. Chem. Soc* 1987, 109, 3493–3494. (b) Beckwith ALJ; O'Shea DM; Westwood SW *J. Am. Chem. Soc* 1988, 110, 2565–2575.
- (20). See Supporting Information.
- (21). Under the reaction conditions the methyl ester was partially hydrolyzed; treatment of the resulting mixture with TMSCHN₂ re-esterifies.
- (22). Li DR; Murugan A; Falck JR *J. Am. Chem. Soc* 2008, 130, 46–48. [PubMed: 18076175]
- (23). The allenyl stannane 36 was prepared by the procedure reported in: Suzuki I; Kiyokawa K; Yasuda M; Baba A *Org. Lett* 2013, 15, 1728. [PubMed: 23517288]
- (24). Corminboeuf O; Overman LE; Pennington LD *J. Am. Chem. Soc* 2003, 125, 6650–6652. [PubMed: 12769572]
- (25). (a) Prévost C *Comptes Rendus Acad. Sci* 1933, 196, 1129–1131. (b) Rodriguez J; Dulcère JP *Synthesis* 1993, 1177–1205.
- (26). Woodward RB; Brucher FV, Jr. *J. Am. Chem. Soc* 1958, 80, 209–211.

- (27). (a) Jacobsen EN; Marko I; Mungall WS; Schroeder G; Sharpless KB J. Am. Chem. Soc 1988, 110, 1968–1970.(b) Kolb HC; VanNieuwenhze MS; Sharpless KB Chem. Rev 1994, 94, 2483–2547.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript







Figure 1.
Representative examples of ryanoid natural products.




Scheme 1.
Retrosynthetic analysis of ryanodol (2).




Scheme 2.
 Synthesis of the ryanodol ABC tricycle.



Scheme 3.
Oxidative dearomatization to form the ryanoid carbon skeleton.



Scheme 4.
Synthesis of Tetracycle 34



Scheme 5.
Synthesis of Diol 43.